학술논문
A novel rapamycin analog is highly selective for mTORC1 in vivo
Document Type
article
Author
Source
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Subject
Language
English
ISSN
2041-1723
Abstract
Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects on glucose homeostasis, lipid metabolism, and the immune system.